For production of short-chain peptide pharmaceuticals in glass-lined or Hastelloy reactors, CBZ-L-phenylglycine is charged as the N-protected aryl-substituted amino acid equivalent in solution-phase fragment condensations. The material is typically pre-dried in a vacuum tray dryer at 40–50 °C under ≤1 kPa absolute pressure until loss on drying by USP <731> falls below 0.5% by weight. The dried acid is dissolved in dichloromethane or tetrahydrofuran at a concentration of 0.25–0.50 mol/L, and the solution is cooled to 0–5 °C in a jacketed stirred tank reactor with a Rushton turbine operating at 1.5 m/s tip speed. Activation is performed with 1.05 equivalent of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1.1 equivalent of 1-hydroxybenzotriazole monohydrate relative to the protected amino acid. The resulting activated ester is held at 0–5 °C for 20–30 min before the amino acid ester component, pre-dissolved in dichloromethane or N,N-dimethylformamide, is added through a dosing line at a rate that does not allow the batch temperature to rise above 8 °C. Under these conditions, the coupling reaction is commonly complete within 2–6 h when monitored by high-performance liquid chromatography according to USP <621> on a C18 column with a 0.1% trifluoroacetic acid/acetonitrile gradient, with the end point defined as residual CBZ-L-phenylglycine below 1.0 area%. The main process conflict in this chemistry is the α-hydrogen acidity of the phenylglycine residue, which permits oxazolone-mediated racemization if the temperature is raised too early or if a strong tertiary amine is charged too quickly.

After the coupling reaction, the batch is quenched with 5% citric acid, washed with 5% sodium bicarbonate and brine, and phase-separated at 20–25 °C. The organic phase is concentrated under reduced pressure at ≤35 °C, and the protected peptide fragment is crystallized by adding n-heptane at a controlled rate of 0.2 L/min while the batch is cooled from 25 °C to 0 °C over 4 h. Filtration is typically performed on a polypropylene filter cloth, followed by washing with cold n-heptane and drying at 35 °C under vacuum. For removal of the carbobenzoxy group, the intermediate is dissolved in tetrahydrofuran:methanol 1:1 v/v and charged to a pressure-rated Hastelloy vessel containing 5 wt% palladium on activated carbon (50% water-wet paste) at a substrate-to-catalyst weight ratio of 20:1. Hydrogenation is conducted at 2–3 bar hydrogen pressure and 20–25 °C for 3–6 h; reaction completion is confirmed by HPLC. The catalyst is removed by filtration through a 0.45 μm polypropylene cartridge, and residual palladium is controlled by inductively coupled plasma optical emission spectrometry to <10 ppm in the isolated peptide amino acid intermediate. A common batch failure is the breakthrough of carbon fines into the crystallizer after polishing filtration, which lowers optical clarity and requires an additional recirculation loop through a 0.2 μm membrane.

What Limits Oxazolone-Mediated Racemization in Mixed Anhydride Couplings at Pilot Scale?

When CBZ-L-phenylglycine is activated as a mixed anhydride for large-scale peptide fragment assembly, the primary process limit is the thermal window between anhydride formation and oxazolone cyclization. In this route, the protected amino acid is dissolved in anhydrous tetrahydrofuran at 0.25 mol/L, cooled to −20 °C in a stainless-steel low-temperature reactor rated for −30 °C, and treated with 1.0–1.2 equivalents of N-methylmorpholine. Isobutyl chloroformate, 1.05 equivalents, is added through a jacketed dosing line over 30–60 min while maintaining the batch at −20 to −15 °C. The mixed anhydride is aged for 15–30 min; the amino acid ester component, pre-cooled to −10 °C in tetrahydrofuran:N,N-dimethylformamide 4:1 v/v, is then charged at a rate that keeps the batch temperature below −10 °C. After 1–2 h, the batch is warmed gradually to 0–5 °C before the work-up. The risk of oxazolone formation increases sharply if the batch exceeds −5 °C during activation or if the isobutyl chloroformate addition is completed in less than 15 min, because local basicity and heat accumulation convert the mixed anhydride into the 2-aryl-4-carboxy-oxazolone intermediate. Once this occurs, the diastereomeric impurity generated in the subsequent coupling step may rise from 0.10–0.15 area% to 1.0–2.0 area% within 10–20 min.

In-process control for the mixed anhydride route uses chiral HPLC on a polysaccharide-based column with a mobile phase of n-hexane:isopropanol 90:10 v/v plus 0.1% trifluoroacetic acid, at a flow rate of 1.0 mL/min. Fractions are pulled at 10 min intervals after the amino component is charged. The diastereomeric excess of the protected peptide intermediate is calculated from the peak areas of the L,L and L,D forms. If the impurity exceeds 0.30 area%, the batch is diverted to a salt formation or recrystallization step rather than proceeding directly to hydrogenolysis. This route is preferred for heat-sensitive peptide sequences because the carbonic acid mixed anhydride generates fewer urea by-products than carbodiimide activation, but it requires stricter moisture control: water content above 0.1% in tetrahydrofuran reduces the yield by hydrolyzing isobutyl chloroformate before activation is complete. Analytical monitoring by Karl Fischer titration is therefore performed before and after reagent addition, with an acceptance limit of ≤100 ppm water in the activation solvent.

In pharmaceutical analytical development, CBZ-L-phenylglycine is used as a chiral derivatizing acid for the determination of enantiomeric excess in primary and secondary amine samples using achiral reversed-phase HPLC. A representative derivatization protocol charges 0.05 mmol of the amine sample into 1.0 mL of dry dichloromethane, followed by 0.055 mmol of CBZ-L-phenylglycine, 0.06 mmol of dicyclohexylcarbodiimide, and 0.01 mmol of 1-hydroxybenzotriazole monohydrate. The mixture is stirred at 20–25 °C for 60–90 min; the dicyclohexylurea precipitate is removed by centrifugation or through a 0.45 μm PTFE syringe filter, and the derivatized diastereomers are evaporated at 35 °C under a nitrogen stream. The residue is reconstituted in methanol:water 70:30 v/v and injected onto a C18 column with 3 μm particles, 150 mm × 4.6 mm, maintained at 30 °C. The mobile phase is acetonitrile:20 mM ammonium acetate buffer pH 5.0 in an isocratic 50:50 v/v composition, with detection at 254 nm. Because the carbobenzoxy chromophore absorbs at 254 nm, low-concentration impurities can be quantified without pre-column fluorescent labeling. Method validation under ICH Q2(R1) typically establishes linearity from 0.05 mg/mL to 1.0 mg/mL, a limit of detection of 0.01 mg/mL, and a limit of quantitation of 0.03 mg/mL for the minor diastereomer. Resolution between the derivatized enantiomers is commonly required to be ≥2.0 according to the system suitability criteria of USP <621>. The procedure is limited by steric hindrance in α-branched amines: for a tertiary-carbon amine with two large side chains, derivatization may require 12–24 h at 0–5 °C and may still leave 5–10% underivatized starting material, which elutes away from the diastereomer peaks but complicates quantitation. Under these conditions, the addition of 0.1–0.2 eq of 4-dimethylaminopyridine improves conversion without increasing racemization, provided the reaction temperature is kept below 5 °C.

Diastereomeric Salt Resolution in Batch Crystallizers with CBZ-L-Phenylglycine

CBZ-L-phenylglycine is used as a chiral acid resolving agent for the preparative separation of racemic amines in pharmaceutical intermediate manufacturing. In this application, the racemic amine is dissolved in an isopropanol:water 9:1 v/v mixture at 75–80 °C, and CBZ-L-phenylglycine is charged at 0.50–0.55 molar equivalent relative to the total amine content. The less soluble diastereomeric salt crystallizes during controlled cooling. The batch is cooled from 75 °C to 15 °C at 2 °C/h in a batch crystallizer equipped with an anchor impeller at 0.5–1.0 m/s tip speed. Seed crystals of the desired salt, when available, are added at 0.5 wt% relative to the theoretical dry product mass at 60–65 °C; this suppresses secondary nucleation and reduces wall scaling. After aging for 4–6 h, the slurry is filtered through a pressure nutsche and washed with cold isopropanol at 0–5 °C. The decomposition of the diastereomeric salt is performed by partitioning between ethyl acetate and 1 M sodium hydroxide at 20–25 °C; the free amine is recovered from the organic phase and distilled or crystallized as the hydrochloride salt. The mother liquor, enriched in the opposite enantiomer, is racemized and recycled when process economics permit; otherwise the remaining CBZ-L-phenylglycine is recovered by acidification with 1 M hydrochloric acid and filtration of the protected acid after cooling.

The limiting factors in this resolution are solvate incorporation and salt decomposition during prolonged residence at elevated temperature. Isopropanol:water 9:1 systems can produce a monohydrate or mixed solvate that contains residual solvent above the ICH Q3C limit for isopropanol, especially if the cake is dried at temperatures above 40 °C without a controlled humid purge. Differential scanning calorimetry according to ASTM E793 can be used to identify low-temperature desolvation events before drying scale-up. For a racemic amine with a melting point near the crystallization temperature, the diastereomeric salt may oil out instead of forming a filterable solid; in that case, replacing 10–20% of the isopropanol with n-butyl acetate raises the oiling-out boundary and allows seed growth. Enantiomeric purity of the isolated amine is monitored after salt decomposition by chiral HPLC on a polysaccharide-based column, and optical rotation is recorded according to USP <781>. Published data for this specific CBZ-protected acid in commercial resolutions varies by substrate, but first-crop enantiomeric excess values above 90% are commonly targeted before recrystallization. The process is not suitable for amines with strong chelating groups, because stable salt hydrates can form and reduce filterability even after slurry cooling is extended to 12 h.

When Borane-Dimethyl Sulfide Reduction Supplies a Chiral N-Protected Amino Alcohol for Asymmetric Ligand Processes

In the preparation of chiral N-protected amino alcohols for asymmetric catalysis and chiral ligand manufacturing, CBZ-L-phenylglycine is charged into anhydrous tetrahydrofuran at 0–5 °C under a nitrogen atmosphere. Borane-dimethyl sulfide complex, 1.2–1.5 equivalents, is added slowly through a sub-ambient dosing line over 60–90 min. The batch temperature is maintained at ≤10 °C during the addition because the reduction of the carboxy group is exothermic and because the dimethyl sulfide by-product increases the vent load. After the addition, the mixture is warmed to 20–25 °C and held for 12–16 h. The reaction is quenched by the controlled addition of methanol at 0–5 °C, followed by 1 M hydrochloric acid to decompose borate complexes. The crude N-Cbz-phenylglycinol is extracted into ethyl acetate, washed with brine, dried over sodium sulfate, and concentrated under vacuum at ≤35 °C. Crystallization from ethyl acetate:n-heptane 1:3 v/v at 0–5 °C provides the amino alcohol as a crystalline solid that is isolated by filtration and dried under vacuum.

The downstream use of this amino alcohol is concentrated in the synthesis of chiral oxazaborolidine-type catalysts and chiral sulfonamide ligands for asymmetric reductions, where the Cbz group is retained during catalyst assembly and replaced later by hydrogenolysis. The process boundary is determined by the stability of the carbobenzoxy group toward borane and by the tendency of the phenyl-substituted amino alcohol to form a borate ester before the quench; if the quench is delayed beyond 24 h at 25 °C, residual borane may lead to partial reductive decomposition of the carbobenzoxy group. Process development reactors for this chemistry require a pressure-rated vent system for dimethyl sulfide and a glass-lined vessel with a temperature probe located below the surface, because density stratification in the reaction mixture can create local hot spots. The isolated N-Cbz-phenylglycinol is typically stored under nitrogen at 2–8 °C, because the free alcohol is hygroscopic and may absorb 1–2% moisture under ambient humidity, which interferes with subsequent catalyst formation. Published data for the use of this specific N-protected amino alcohol in commercial asymmetric transformations is limited, but laboratory-scale ligand preparations have been reported with batch sizes below 1 mol for oxazaborolidine-catalyzed ketone reductions.

In route scouting for β-lactam antibiotic intermediates and peptidomimetic protease inhibitor scaffolds, CBZ-L-phenylglycine is evaluated as a protected L-aryl glycine surrogate that allows the introduction of a phenylglycine residue without a free amino group. The compound is not a direct substitute for the D-phenylglycine side chain used in ampicillin or cephalexin coupling to 6-aminopenicillanic acid or 7-aminodesacetoxycephalosporanic acid; the L-configuration produces a diastereomeric acylated β-lactam with different pharmacopoeial potency and degradation behavior. When comparison batches are run with CBZ-L-phenylglycine and CBZ-D-phenylglycine under the same mixed anhydride or carbodiimide activation conditions, the L-isomer exhibits similar coupling kinetics but would not meet the optical rotation and related substances specifications required for the marketed D-phenylglycine antibiotics. The value of the L-protected derivative in this area lies mainly in the preparation of L-phenylglycine-containing peptide fragments for structure-activity relationship studies and in the synthesis of reference impurities used to validate HPLC methods for amino acid side-chain diastereomers. A typical reference impurity batch is prepared by coupling CBZ-L-phenylglycine to a 6-aminopenicillanic acid ester under controlled conditions, followed by hydrogenolytic deprotection using 5 wt% palladium on carbon at 2–3 bar and 20–25 °C. The isolated impurity is lyophilized and characterized by mass spectrometry, optical rotation according to USP <781>, and HPLC purity according to USP <621>. In such impurity qualification programs, the material is not used as a pharmaceutical ingredient but as a reference standard; its certificate of analysis should include residual palladium by inductively coupled plasma mass spectrometry, residual solvents by USP <467>, and water content by Karl Fischer titration. The operational boundary for this application is the purification burden: the L-isomer often co-elutes with the D-isomer on achiral C18 columns, and the separation of the two diastereomers requires a polysaccharide-based chiral column or a cryogenic chromatography step that increases the cost of multi-hundred-gram reference standard campaigns. Published data for CBZ-L-phenylglycine as a direct large-scale intermediate in marketed β-lactam antibiotics is limited; its use is therefore concentrated in analytical reference preparation and exploratory medicinal chemistry rather than primary API manufacturing.